NASDAQ NMS - GLOBAL MARKET · PROK
+3.10% · +$0.0600 · Vol 579.7K
Market closed · last close 4:00 PM ET · price as of 16:54:07 ET
Prokidney Corp

Prokidney Corp

Biotechnology
$1.83
Card
Relationship Map

Follow $PROK

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $PROK by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
PROK
Prokidney Corp
Tue Sep 22 · last completed session · Markets closed · resumes Wed 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Tue Sep 22 · last completed session · Markets closed · resumes Wed 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PROK moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PROK catalysts
About Prokidney Corp
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2022
Employees
231
Country
US

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.77
Day high
$1.86
Day low
$1.77
Previous close
$1.77
52W high
$3.30
-44.55% from high
52W low
$1.33
25% of range
Market cap
$370.8M
Beta
0.94
Shares out
208.9M
Volume
579.7K
0.38× rel vol
Avg volume
1.5M
VWAP
$1.83
Price history computed in-house
1W
-1.08%
1M
+13.66%
3M
+7.65%
1Y
-33.21%
YTD
-18.30%
SMA 50 $1.67 · above
SMA 200 $1.93 · below
52W position 25%

PROK overview

Veridion Score
38
Registered · 2026-09-22
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PROK.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PROK Form 4 filings
Public disclosures

Congress activity in PROK

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PROK in the cached public ledger.

Federal contracts

PROK contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PROK in this window.
Lobbying spend

PROK lobbying filings, year to date.

Registered lobbying filings matched to Prokidney Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PROK in this window.
Loading news for PROK
Analyst ratings
Sovereign unlock shows live analyst consensus for PROK.
Options
Sovereign unlock shows live options positioning for PROK.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.